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Chakrabarty et al. show that Interleukin-
10 increases Ab plaque deposition and
impairs cognition in APP mice. This is
mechanistically linked to decreased
microglial Ab phagocytosis and
increased ApoE expression and
sequestration in plaques, consistent with
ApoE’s role as a pathological chaperone.
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Anti-inflammatory strategies are proposed to have
beneficial effects in Alzheimer’s disease. To explore
how anti-inflammatory cytokine signaling affects Ab
pathology, we investigated the effects of adeno-
associated virus (AAV2/1)-mediated expression of
Interleukin (IL)-10 in the brains of APP transgenic
mouse models. IL-10 expression resulted in in-
creased Ab accumulation and impaired memory in
APPmice. A focused transcriptome analysis revealed
changes consistent with enhanced IL-10 signaling
and increased ApoE expression in IL-10-expressing
APP mice. ApoE protein was selectively increased
in the plaque-associated insoluble cellular fraction,
likely because of direct interaction with aggregated
Ab in the IL-10-expressing APPmice. Ex vivo studies
also show that IL-10 and ApoE can individually impair
glial Ab phagocytosis. Our observations that IL-10
has an unexpected negative effect on Ab proteosta-
sis and cognition in APPmouse models demonstrate
the complex interplay between innate immunity and
proteostasis in neurodegenerative diseases, an inter-
action we call immunoproteostasis.
INTRODUCTION
Altered central nervous system (CNS) proteostasis, character-
ized by accumulation of extracellular or intracellular proteina-
ceous deposits, is thought to be a key trigger of many neurode-
generative disorders (Golde et al., 2013). There is considerable
evidence that various assemblies of the aggregated proteins
that form these inclusions can activate the innate immune sys-
tem which, in turn, can contribute to the degenerative cascade.
There is also growing evidence that alterations in innate immune
signaling can play a key role in regulating proteostasis of key
pathogenic proteins linked to neurodegenerative disorders (re-viewed in Czirr and Wyss-Coray, 2012). We term this complex
interplay between the innate immune system and proteinopathy
‘‘immunoproteostasis.’’ In a contextually dependent fashion, im-
munoproteostasis can have positive or negative effects on the
proteinopathy and degenerative phenotype. Because of these
effects and the plethora of therapeutic targets in the innate
immune system, there is considerable interest in manipulating
immunoproteostasis for potential disease modification in neuro-
degenerative diseases.
Two long-standing and interrelated hypotheses in the
Alzheimer’s disease (AD) field relevant to immunoproteostasis
are that (1) proinflammatory activation of innate immunity can
enhance Ab accumulation and thereby initiate or accelerate
pathological cascades in AD; and (2) anti-inflammatory strate-
gies reduce Ab accumulation and, through synergistic or inde-
pendent mechanisms, could also be neuroprotective. We and
others have directly tested the first of these hypotheses and
found little experimental evidence to support it (Boissonneault
et al., 2009; Chakrabarty et al., 2010a, 2010b, 2011; El Khoury
et al., 2007; Herber et al., 2007; Naert and Rivest, 2011; Shaftel
et al., 2007). These studies showed that manipulations that skew
innate immunity toward a proinflammatory state consistently
reduce Ab accumulation in transgenic mouse models largely
by enhanced microglial clearance of Ab. Other studies using
pharmacologic and genetic means to suppress innate immune
activation in similar mouse models have revealed conflicting re-
sults. Some manipulations designed to suppress innate immune
activation appear to decrease Ab accumulation and improve AD-
associated phenotypes in these models, whereas others have
deleterious effects and promote Ab accumulation and worsen
AD phenotypes (Chakrabarty et al., 2012; El Khoury et al.,
2007; Kiyota et al., 2010; Maier et al., 2008; Richard et al.,
2008; Vom Berg et al., 2012). Furthermore, clinical trials with
anti-inflammatory agents have failed to clearly show any evi-
dence of beneficial effect in AD patients (Breitner et al., 2011;
Leoutsakos et al., 2012).
Given conflicting data on how suppressing immune activation
can alter Ab proteostasis, we explored the effects of Interleukin
(IL)-10 expression in amyloid precursor protein (APP) transgenic
mouse models. IL-10 is a key cytokine that represses excessiveNeuron 85, 519–533, February 4, 2015 ª2015 Elsevier Inc. 519
inflammatory responses and inhibits the effector functions in
macrophages and myeloid cells by inhibiting inflammatory cyto-
kine pathways (Banchereau et al., 2012). We tested the effect of
recombinant adeno-associated virus (AAV2/1)-mediated intra-
cranial expression of murine IL-10 in two transgenic APP
models: TgCRND8 mice (Chishti et al., 2001) and Tg2576 mice
(Hsiao et al., 1995). We find that IL-10 expression leads to
increased amyloid loads, decreased levels of immediate early
genes and synaptic markers, worsened cognitive behavior,
reduced microglial Ab phagocytosis, and increased ApoE
expression and its sequestration within insoluble amyloid
plaques.
RESULTS
IL-10 Exacerbates Ab Plaque Burden in APP Transgenic
Mice without Affecting APP Metabolism
We generated recombinant AAV vectors encoding murine IL-10.
Transduction of human embryonic kidney 293T (HEK293T) cells
with the IL-10 expression construct showed that the IL-10 ex-
pressed from the AAV vector was efficiently secreted (Figure S1A
available online). When primary neuroglial cultures were trans-
duced with AAV2/1-IL-10 and then subsequently treated with
fibrillar Ab42 (fAb42) or lipopolysaccharide (LPS), IL-10 sup-
pressed both fAb42- and LPS-induced inflammatory immune
activation (Figure S1B).
We next evaluated the effects of IL-10 expression in two
different APP mouse models. Two independent cohorts of
neonatal transgenic TgCRND8 (Tg) mice and nontransgenic
(nTg) littermates were injected with AAV2/1-IL-10 or AAV2/1-
GFP in the cerebral ventricles and then analyzed after 5 or
6 months (cohort A, Figure 1; cohort B, Figure S2). We have pre-
viously shown that AAV2/1-GFP serves as an appropriate control
for these types of studies (Chakrabarty et al., 2010a, 2010b).
Following delivery of AAV2/1-IL-10, IL-10 was significantly
increased in the brains and plasma of TgCRND8 (IL-10/Tg) and
nTG (IL-10/nTg) mice (Figures S1D and S1E). In the CRND8
cohort A, analysis of Ab plaque burden showed that IL-10 signif-
icantly increased total plaque burden by greater than 50% in the
hippocampus and cortex of CRND8 mice, while Thioflavin-S
(ThioS)-positive dense core compact plaques increased by
38% (Figures 1A and 1B). Biochemical analysis of Ab levels
in sequentially extracted RIPA-, SDS-, and formic-acid (FA)-sol-
ubilized mice brain lysates showed significantly increased levels
of SDS-solubilized Ab and FA-solubilized Ab in IL-10/Tg mice
(Figure 1C). There was no change in RIPA-soluble Ab (Figure 1C).
Both the RIPA-soluble and SDS-soluble mouse brain extracts
were separated by PAGE and examined using the Ab N-termi-
nus-specific 82E1 monoclonal antibody (mAb). Levels of 82E1-
immunoreactive, low-molecular-weight, RIPA-solubilized Ab
oligomers were unchanged in IL-10/Tg and control/Tg mice
(data not shown). In the SDS fraction, an 82E1 immunoreactive
band migrating at 8 kDa was slightly increased in a select
group of IL-10/Tg mice (Figure 1D, asterisk). Immunofluores-
cence analysis of Ab in microglia surrounding plaques showed
increased Ab accumulation within microglial cells in IL-10/Tg
mice (Figure 1E). Notably, in the second cohort of CRND8 mice
tested, we observed similar results on Ab (Figure S2). We further520 Neuron 85, 519–533, February 4, 2015 ª2015 Elsevier Inc.tested whether accumulated Ab in IL-10-expressingmice lead to
increased phosphorylated tau. However, we found no significant
changes in endogenous mouse tau phosphorylation in IL-10/Tg
mice compared to control/Tg mice (Figure S3).
We next examined whether IL-10 affects plaque deposition in
another APP transgenic mousemodel in a different experimental
paradigm. Eight-month-old Tg2576 mice were injected in the
hippocampus with AAV2/1-IL-10 or AAV2/1-GFP and analyzed
at 13 months of age. Soluble IL-10 was elevated in the brains
of AAV2/1-IL-10 injected mice (14.2 ± 4.7 ng/ml; 4.33 over con-
trol). Immunohistochemical analysis of Ab plaque burden
showed an overall increase of 43% in the brains of IL-10-ex-
pressing Tg2576 mice compared to GFP-expressing mice
without any change in ThioS-positive plaques (Figures 2A and
2B). ELISA analysis of Ab showed increased guanidine-hydro-
chloride (GN-HCl)-extractable insoluble Ab42 but no changes
in Ab40 levels and unchanged levels of TBSx-soluble Ab
(Figure 2C).
We performed an initial series of studies to evaluate IL-10-
induced changes in APP gene expression, its cleavage prod-
ucts, or Ab degrading enzymes. No significant changes in full-
length APP, CTFa, CTFb, or PrPc were noted in CRND8 and
Tg2576 cohorts (Figures S4A and S4C–S4E). Endogenous
mouse APP and Ab levels were not altered in nTg mice ex-
pressing IL-10 or GFP (Figures S4B, S4C, and S4F). Quantitative
real-time PCR of mouse APP, beta-secretase 1 (BACE1), insulin-
degrading enzyme, and human APP transcript levels did not
reveal any significant alterations in IL-10-expressing mice (Fig-
ure S4G). Although neprilysin (NEP) mRNA appeared to be low-
ered in IL-10/Tg mice (Figure S4G), NEP protein levels were not
altered (Figure S4H).
IL-10 Exacerbates Context and Fear Tone Memory in
TgCRND8 Mice
We assessed hippocampus-dependent contextual and amyg-
dala-dependent tone fear-conditioned memory in CRND8 mice
(cohort A) (Figure 3A) (Hanna et al., 2012). All mice actively
explored the novel environment of the training chamber and
spent <3% of the total exploration time on pauses or immobility,
with no significant differences between the groups (Figure 3B).
The immediate freezing response to the foot shock significantly
differentiated the groups and was lower in both IL-10/Tg
(13.6%) and control/Tg (25.2%) mice compared to IL-10/nTg
(40.3%) and control/nTg (34.9%) mice, respectively (Figure 3B).
The freezing response of males and females was comparable,
with no significant interactions involving gender (p = 0.377,
Gender 3 Group interaction effect). The IL-10/Tg mice showed
decreased freezing during contextual memory test compared
to the control/nTg and control/Tg groups, which indicates the
decline in their contextual fear memory (Figure 3C). Control/Tg
mice showed comparable context memory to the memory of
nTg mice (Figure 3C). During the tone test, the groups did not
differ in their exploration of the modified chamber during the
phase preceding the presentation of the tone (Figure 3D). IL-
10/Tg mice froze significantly less than control/nTg and IL-10/
nTg mice during the presentation of the CS tone, while control/
Tg mice showed a trend of lower freezing response than con-
trol/nTg mice (Figure 3D).
Figure 1. IL-10 Increases Ab Deposition in Tg CRND8 Mice
(A) Neonatal CRND8 mice were injected with either AAV2/1-IL-10 or AAV2/1-GFP (control) in the cerebral ventricles and analyzed after 6 months for Ab plaque
pathology using anti-AbmAb 33.1.1, anti-ubiquitin, and ThioS staining. Both Ab staining protocols depict increased Ab deposition in IL-10/Tg mice compared to
controls, whereas ubiquitin staining around individual plaques was unaltered. Scale bars, 600 mm (whole brain) and 125 mm (cortex and hippocampus). n = 8–10
mice per group for immunohistochemistry and n = 6 per group for ThioS staining.
(B) Quantification of Ab plaque shows significantly increased amyloid plaque burden (immunostained with anti-Ab 33.1.1) and total number of ThioS cored
plaques in IL-10/Tg mice compared to control/Tg mice. Data represent mean ± SEM. n = 8-10/group for immunohistochemistry and n = 6 mice/group for ThioS
staining. ***p < 0.001, unpaired two-tailed t test.
(C) Biochemical analyses of sequentially extracted Ab42 and Ab40 levels by end-specific sandwich ELISA show significantly increased SDS-soluble and formic-
acid-extracted insoluble Ab levels in IL-10/Tg compared to control/Tg mice. No change was detected in RIPA-extracted Ab42 and Ab40. Data represent mean ±
SEM. n = 6 mice per group. *p < 0.05, ***p < 0.001, two-way ANOVA with Tukey’s multiple comparison test.
(D) Representative 82E1 immunoblots of 6-month-old IL-10/Tg mice show no significant changes in Ab oligomers compared to control/Tg mice. The left lane
shows a representative aggregated Ab42 preparation. A band migrating8 kDa is upregulated in select IL-10/Tg mice (asterisk, right). Molecular weight markers
are indicated on the right (in kilodaltons). The lower panel represents the 82E1 blot reprobed with anti-actin antibody to depict loading amount. n = 6 mice per
group.
(E) Representative Z slice section analysis of 4G8 immunoreactive Ab (Alexa Fluor 488) and Iba-1-labeled microglia (Alexa Fluor, 594) shows increased Ab
accumulation in microglia surrounding amyloid plaques in IL-10/Tg mice. DAPI, in blue, denotes nucleus. Scale bar, 20.5 mm. n = 3 mice per group.
See also Figures S1–S4.IL-10 Reduces c-FOS and zif268 Transcripts as well as
Protein Levels of Synaptophysin and Total PSD95
RNA analysis showed that IL-10/Tg mice displayed 62.8%
reduction in the c-Fos transcript compared to control/Tg
mice (nCounter GX Mouse Inflammation array; log ratio =1.315; p = 0.0250; q value = 0.00913). No significant change
in c-fos transcript was detected in IL-10/nTg mice compared
to control/nTg mice. RNA levels of zif268, a key player in
neuronal plasticity and learning, is also decreased in IL-10/
Tg mice compared to control/Tg mice (log ratio = 0.97;Neuron 85, 519–533, February 4, 2015 ª2015 Elsevier Inc. 521
Figure 2. IL-10 Increases Ab Deposition in Tg2576 Mice
(A) Eight-month-old Tg2576 mice were injected in the hippocampus with AAV2/1-IL-10 or AAV2/1-GFP (Control), aged for 5 months, and analyzed at 13 months.
Representative brain sections (cortex and hippocampus) stained with anti-Ab mAb 33.1.1 show that Ab plaque burden is increased in IL-10-expressing mice
compared to control. No significant changes in ThioS-stained cored plaques was observed. Scale bars, 125 mm (whole brain) and 75 mm (cortex and hippo-
campus). n = 5–7 mice per group.
(B) Quantitative burden analysis of Ab plaque deposits show significantly increased Ab plaque immunoreactivity but no change in ThioS reactive plaques in IL-10-
expressing mice compared to controls. Data represent mean ± SEM. n = 5–7 mice per group. *p < 0.05, unpaired t test.
(C) Biochemical analyses of Gn-HCL-solubilized Ab42 and Ab40 levels measured by ELISA show significantly increased insoluble Ab42 levels in IL-10-expressing
mice compared to controls, but no significant differences in soluble Ab levels (TBSx fraction) are seen. Data represent mean ± SEM. n = 5-7 mice per group. *p <
0.05, unpaired t test.
See also Figure S4.p = 0.00038; q value = 0.00029). We further examined levels of
the presynaptic vesicle protein, synaptophysin, by immuno-
histochemistry and immunoblotting and found that IL-10/Tg
mice have 27.5% less synaptophysin than control/Tg (Figures
4A–4C). In addition, though phospho-PSD95 protein is un-
changed in IL-10/Tg, total levels of PSD95 are reduced by
50% in IL-10/Tg mice compared to control/Tg mice (Figures
4A and 4B).
IL-10 Expression Alters Innate Immune Homeostasis in
CRND8 Mice and Has Modest Effects on Primary
Microglial Phagocytosis
We investigated how IL-10 alters the immune milieu and Ab
phenotypes using (1) immunophenotyping and immunohisto-
chemical techniques and (2) functional assays to evaluate the
phagocytic potential of murine microglia and astrocytes. We
analyzed how IL-10 affects the expression of M1 and M2 pheno-522 Neuron 85, 519–533, February 4, 2015 ª2015 Elsevier Inc.typic markers in the CNS (Gordon and Taylor, 2005) (Figure 5A).
Quantitative real-time PCR of IL-10/Tg or control/Tg mice and
their nTg littermates demonstrate a significant increase in Ym-
1 in both IL-10/Tg and IL-10/nTg mice compared to genotype-
matched control mice. MRC-1, arginase, or transforming growth
factor b (TGF-b) transcript levels did not reach statistical signifi-
cance. None of the M1-specific markers (IL-1b, IL-6, iNOS)
showed significant alterations.
No gross morphological changes in the microglial or astrocyte
processes were observed (Figure 5B). Immunoblotting with
cd11b and glial fibrillary acidic protein (GFAP) showed a trend to-
ward elevation in the IL-10/Tg mice (Figure 5C). Using either
GFAP or tomato lectin staining, we found that the number of
astrocyte nuclei or microglial nuclei within a predefined area of
100 mmdiameter around ThioS-positive Ab plaques was also un-
changed (Figure 5D). Similar results were observed in the
Tg2576 cohort injected with AAV2/1-IL-10 (Figure S5).
Figure 3. IL-10 Worsens Cognitive Impair-
ment in TgCRND8 Mice
(A) Schematic representation of the stimuli pa-
rameters used in delay conditioning paradigms.
On day 1, mice were exposed to two pairings of an
auditory conditioned stimulus (CS) and a brief
coterminating foot shock (US). After a day of re-
covery (day 2), the memory of the association
between the training context and the US was
evaluated on day 3, and the memory of the asso-
ciation between the tone CS and US was evalu-
ated on day 4.
(B) Mean percent of freezing exhibited by IL-10-
expressing and control groups during training. All
mice showed comparable activity in the training
chamber, pausing briefly during their exploration
of the novel environment of the chamber before
the onset of the first tone stimulus. The evaluation
of freezing response immediately following the
presentation of a foot shock during training
showed that both the control/Tg and IL-10/Tg
mice froze less compared to control/nTg mice and
IL-10/nTg mice, respectively (n = 8–12 per group).
**p < 0.01, modified least significant difference
(MODLSD) Bonferroni t tests. Data represent
mean ± SEM.
(C and D) In the context test, IL-10/Tg mice
showed significantly lower rates of freezing
compared to control/Tg mice as well as nTg lit-
termates expressing GFP or IL-10 indicative of
severe memory deficits (C). During the tone test,
there was no difference in the freezing response of
the mice in the modified context of the chamber at
the stage preceding tone presentation (Pre CS in D). During tone presentation (Post CS in D), IL-10/Tg mice showed significantly weaker tone fear memory
compared to their control/nTg and IL-10/Tg littermates, while the control/Tg mice showed a trend in freezing decrease compared to control/nTg (p = 0.07). n = 8–
12 mice per group. *p < 0.05, **p < 0.01, ***p < 0.001, MODLSD Bonferroni t tests. Data represent mean ± SEM.Next, we investigated the effect of recombinant IL-10 following
fAb42 treatment of primary murine microglial cells. In contrast to
the broad immunosuppressive effect of IL-10 on mixed neuro-
glial cultures, IL-10 showed mixed effects on fAb42-treated mi-
croglia. For example, IL-10 attenuated fAb42 induced CCL5,
CXCL10, TLR1, and TNFa expression but augmented CCL2
and CCL8 expression (Figure 6A). We then examined functional
effects of IL-10 on the phagocytic potential of primarymurinemi-
croglia and astrocytes cultured in vitro (Figures 6B and 6C; Fig-
ure S6). Wild-type murine microglia or astrocytes were treated
with recombinant cytokines, followed by the addition of preag-
gregated fluorescent fAb40 or fAb42. Flow cytometric and
microscopic analysis showed that IL-10 treatment leads to
decreased internalized fAb40 in IL-10-treated microglia
compared to vehicle-treated control microglia (Figures 6B and
6C). Following 1 hr of Ab40 incubation, microglial cells were
chased for 24 hr in fresh medium containing no Ab. IL-10-treated
cells showed a trend toward decreased clearance of internalized
Ab40 at 1 hr (p = 0.0533, one-tailed t test) and 3 hr (p = 0.13, one-
tailed t test) following ‘‘chase’’ in fresh medium (Figure S6A).
Simultaneously, IL-6 treatment resulted in increased fAb40 inter-
nalization compared to vehicle-treated microglia after 1 hr incu-
bation (Figure S6B). In these studies, IL-10 did not affect fAb42
uptake by microglia at the time points tested (Figure 6B). Astro-
cytes are relatively resistant to Ab phagocytosis under similarexperimental conditions (Chakrabarty et al., 2012). Flow
cytometric analysis of fAb40 or fAb42 phagocytosis by murine
astrocytes showed that IL-10 treatment does not alter Ab inter-
nalization (Figure S6C), whereas IL-6 treatment leads to a signif-
icant increase in astrocytic Ab internalization after 1 hr incubation
(Figure S6B).
Integrated Systems Approach Identifies Inflammatory
Pathway Changes in Response to IL-10 Expression in
APP Mice
We used NanoString nCounter GX mouse inflammation gene
expression arrays to perform expression profiling of RNAs that
are altered by IL-10 in APPmice brain. Of the 179mRNAs initially
tested, 21 transcripts were significantly altered, including che-
mokines and complement pathway genes (q value < 0.05; Fig-
ure 7A). In a follow-up study, we constructed a Neurodegenera-
tion custom array (manufactured by NanoString) composed of
key inflammatory and proteostasis mediators, including genes
most upregulated in the GX Mouse Inflammation array and other
known mediators of neurodegenerative pathways (Table S1). Of
the 240 genes tested in this array, we found that 140 genes were
significantly differentially expressed in IL-10/Tgmice (99 upregu-
lated, 41 downregulated, q value < 0.05; Figures 7B and 7C;
Table S2), and 47 genes were differentially expressed in IL-10/
nTg mice (45 upregulated, 2 downregulated, q value < 0.05;Neuron 85, 519–533, February 4, 2015 ª2015 Elsevier Inc. 523
Figure 4. IL-10-Induced Cognitive Impairment Is Accompanied by
Reduced Synaptic Proteins
(A and B) Synaptophysin, PSD95, and phosphorylated PSD95 (pSer295
PSD95) levels in 6-month-old IL-10/Tg and control/Tg mice. Molecular weight
markers are indicated on the left (in kilodaltons). All blots were simultaneously
reprobed with anti-actin antibody to depict loading amount. Intensity analysis
(mean ± SEM) of immunoreactive bands of interest were normalized to b-actin
(B). n = 5 mice per group. *p < 0.05, unpaired two-tailed t test.
(C) Synaptophysin immunoreactivity was decreased in both the cortex and
hippocampus of IL-10/Tg mice compared to control/Tg. IHC, immunohisto-
chemistry. Scale bar, 150 mm, n = 5 per group.
524 Neuron 85, 519–533, February 4, 2015 ª2015 Elsevier Inc.Figures S7AandS7B; Table S3) compared to genotype-matched
controls. While the magnitude of change for common differen-
tially expressed genes upon IL-10 expression is often greater in
the nTg mice, the number of differentially expressed genes in
Tg mice is significantly greater (p < 0.0002, two-tailed Z test),
indicating a more diverse effect of IL-10 in the Tg mice. Overall,
the gene classes and pathway components altered most signifi-
cantly in Tg and nTg mice were similar: chemokines (Tg: Ccl8,
Ccl5; nTg: Ccl2, Ccl8), complements (Tg: C4a/4b, c3ar1, c1qb,
c1qa; nTg: c1qa, C4a/4b, c1qb,), FcgRs (Tg: FcgR3a; nTg:
FcgR2b), and immune signaling mediators (Tg: HLA-DRB1;
nTg: Ly86, Ms4a6a, Ptpn6, Ctsc) (Figures 7C and S7B).
We used the Ingenuity Pathway Analysis (IPA) tool to identify
biological pathways that are affected by overexpression of IL-
10 in Tg and nTgmice. Differentially expressed genes weremap-
ped to canonical pathways, which highlight individual immune
and inflammatory signaling pathways that are most enriched
for up- or downregulated genes in both the Tg and nTgmice (Fig-
ures 7D and S7C; for a full list of altered pathways in Tgmice, see
Table S4). Seven of the nine most significantly altered pathways
that we examined in the Tg mice included at least one directly
overlapping gene with the IL-10 signaling pathway, supporting
a role between IL-10 expression and downstream activation of
these pathways. In the IL-10/Tg mice, pattern recognition and
acute phase response pathways were the most significantly
altered. In the IL-10/nTg mice, all the pathways affected have
been classically defined as part of IL-10 signaling by multiple
groups (Sabat, 2010; Shouval et al., 2014). We further applied
the differential rank conservation (DIRAC) method to quantita-
tively measure how network expression ordering differs within
and between phenotypes (Eddy et al., 2010); in this case, we
included all measured genes in the analysis, as opposed to re-
stricting the focus on differentially expressed genes as in IPA.
Using DIRAC, we were able to identify multiple pathways in
both Tg and nTg mice that were consistently reordered between
IL-10 and control cohorts, so that these pathways could be used
as statistically significant and accuratemolecular classifiers (Fig-
ure 7E). Notably, the changes captured in these pathway signa-
tures, especially among nTg mice, do not necessarily reflect
pathway-level activation or repression in response to IL-10 over-
expression but often more subtle changes that manifest as rela-
tive changes in the expression levels of different components
within a single pathway. In summary, we identified eight path-
ways that accurately distinguished between IL-10/Tg mice and
control/Tg mice but were not significantly changed in nTg mice
(100% of samples classified correctly by DIRAC) (Figure 7E;
Table S5). The motivation of this study was not to develop
Figure 5. IL-10 Expression Leads to anM2Phenotype and Does Not Affect Astrogliosis or Plaque Engagement of Astroglia in TgCRND8Mice
(A) Sustained IL-10 production leads to a partial M2 phenotype in 6-month-old Tg and nTg littermate brains in CRND8 mice. Quantitative real-time PCR dem-
onstrates that IL-10/Tgmice have elevated levels ofM2 phenotypemarker, Ym-1, but show no significant changes inMRC1 or arginase (Arg). Analysis of threeM1
phenotype markers, IL-6, iNOS, or IL-1b, showed no changes. n = 2–3 mice per group; each sample was tested in triplicate. ***p < 0.001, one-way ANOVA with
post hoc Tukey’s test. Data represent mean ± SEM.
(B) Representative images of Iba-1 (microglia) and GFAP (astrocyte) immunoreactivity in intact hippocampus (top) and higher magnification of selected area of
interest (bottom) from control/Tg and IL-10/Tg mice is shown. Insets depict individual cells (high magnification) from corresponding low-magnification panels.
Scale bars, 125 mm (top), 25 mm (bottom), and 12.5 mm (insets, bottom). n = 6 mice per group.
(C) Representative immunoblot and densitometric analysis of normalized levels of GFAP and cd11b obtained from 6-month-old IL-10/Tg and control/Tg mice.
Molecular weight markers are indicated on the left (in kilodaltons). The lower panels represent blots reprobed with anti-actin antibody to depict loading amount.
n = 5 mice per group; p > 0.05, one-way ANOVA with Tukey’s multiple comparison test. Data represent mean ± SEM.
(D) IL-10 expression does not alter astrocytic or microglial engagement around cored Ab plaques. The number of astrocytes (GFAP-Cy3) and microglia (Dylight
594 conjugated tomato lectin) engaged closely with the ThioS reactive plaques were quantified by counting the number of DAPI-positive nuclei (restricted by a
circular area of 100 mmdiameter around each plaque core, as depicted by the white circle). Data represent mean ± SD. Scale bar, 25 mm. n = 6–7mice per group,
ten plaques per mouse.
See also Figure S5.
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Figure 6. Recombinant IL-10 Attenuates fAb40 Uptake by Primary Glia
(A) List representing log ratio changes of differentially expressing genes in primary murine microglia treated with 10 mM fAb42 or IL-10, alone or in combination,
following analysis by NanoString Inflammation GX array (q = 0.05). n = 3 per group. A selected set of altered transcripts is shown as fold ratio change over naive
glia. n = 2–3 per treatment.
(B) IL-10 treatment decreases microglial phagocytosis of fAb40 but does not affect fAb42 uptake. Flow cytometric analysis for the presence of Ab42-Hilyte555 or
Ab40-Hilyte488 in primary mouse glia cells was conducted following exposure to Ab or vehicle control for various times (15min to 1 hr). Data represent percent of
microglial population positive for 555 nm or 488 nm fluorescence (mean ± SEM). *p < 0.05, **p < 0.01, unpaired two-tailed t test.
(C) Representative pictograms depicting flow cytometric (fluorescence-activated cell sorting; FACS) and microscopic analysis of IL-10- or vehicle (Control)-
treated primary microglia internalizing fAb40-488 nm at different time points.
See also Figure S6.
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Figure 7. Transcriptome Profile of TgCRND8 Mice in Response to IL-10
(A) List representing log ratio changes of differentially expressing genes in IL-10/Tg mice compared to control/Tg mice as analyzed by the NanoString GXMouse
Inflammation array (q = 0.05). n = 3 per group.
(B) Volcano plots highlighting differential expression of genes with IL-10 overexpression in IL-10/Tg compared to control/Tg mice as analyzed by NanoString
Neurodegeneration custom array. Orange circles indicate statistically significant changes with fold change <2, and blue circles represent fold changes >2 (q <
0.05). n = 6 mice per group.
See Tables S1 and S2.
(C) Representative rank-ordered list of genes that are differentially upregulated in response to IL-10 expression in Tg mice. q < 0.05; n = 6 mice per group.
(D) Network analysis of differentially expressed genes in TgCRND8mice. All differentially expressed genes (q < 0.05) were submitted to IPA for canonical network
analysis. Nine significant networks with known connections to AD are shown. Among the genes submitted (140 for APP mice), these nine networks include 55
genes. Differentially expressed genes from the IL-10 network are all contained within the IL-10 subnetwork circle. Blue edges connect genes to shared networks.
Gold edges denote literature connections between ApoE and IL-10 canonical pathway genes. n = 6 mice per group.
(E) DIRAC output of rank-ordered network alterations in response to IL-10 signaling in APP mice.
See also Figure S7 and Tables S1, S2, S3, S4, and S5.classifiers; however, gene expression patterns within these
pathways that accurately distinguish between IL-10 and control
groups provide good measures of confidence for network-level
differences. Moreover, these pathways represent networks
that are potentially altered in APP mice uniquely in response to
IL-10 overexpression.IL-10 Increases ApoE Expression and Results in ApoE
Redistribution within Amyloid-Plaque-Associated
Insoluble Brain Homogenate
Analysis of transcriptome changes in IL-10-expressing mice us-
ing the custom NanoString array showed that IL-10 expression
increased ApoE RNA levels in both Tg ([1.73, p = 1.43 3 106)Neuron 85, 519–533, February 4, 2015 ª2015 Elsevier Inc. 527
Figure 8. IL-10-Induced ApoE Is Redistributed to Insoluble Plaque-Associated Cell Fraction and Impairs Microglial Uptake of Ab
(A and B) Representative anti-ApoE immunoblots from sequentially extracted brain lysates of TgCRND8 mice. In an intensity analysis, immunoreactive bands
of interest for the RIPA and SDS lysates were normalized to b-actin, and those for FA lysates were normalized to dry weight of the hemibrain. Molecular
weight markers are indicated (in kilodaltons). Data represent mean ± SEM. n = 6–7 per group. ***p < 0.001, one-way ANOVA with Tukey’s multiple
comparison test.
(C and D) Representative ThioS-stained Ab plaque shows increased plaque-associated ApoE in IL-10/Tgmice cortex (C). Representative GFAP-stained sections
also demonstrate selective increase in plaque-associated ApoE in IL-10/Tg mice (D). DAPI represents cellular nuclei. n = 3–6 per group.
(legend continued on next page)
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and nTg ([1.53, p < 0.05) mice (Tables S2 and S3). We observed
a similar effect on ApoE transcription in AAV2/1-IL-10-trans-
duced primary mixed neuroglial cultures derived from wild-type
mice (Figure S8A). We did not find any significant changes in
ApoE protein in sequentially extracted RIPA and SDS brain ly-
sates of IL-10/Tg and control/Tg mice (Figure 8A). However,
increased levels of ApoE and cleavage products were found in
the insoluble formic-acid-extracted IL-10/Tg mice brain lysates
([3.873 compared to control/Tg, p < 0.005), suggesting that
IL-10 increases ApoE expression and alters its compartmentali-
zation in Tg mice (Figure 8B). Immununofluorescence demon-
strated that, as expected, ApoE was localized within astrocytes
in both IL-10/Tg and control/Tg mice (Figure S8B). In the IL-10/
Tg mice, ApoE immunostaining was also selectively increased
within Ab plaques, which is consistent with the increased ApoE
sequestration in the formic acid biochemical fraction (Figures
8C and 8D).
To investigate whether ApoE can increase amyloidosis by
directly affecting glial phagocytosis, we explored how ApoE-
conditioned media affects glial uptake of fluorescent Ab. To
recapitulate in vivo conditions, we transduced the astrocytes in
mixed glial culture with either rAAV2/1-GFP or rAAV2/1-ApoE
and maintained the mixed culture for 3 days (Figures S8C and
S8D). Robust overexpression of ApoEwas confirmed bywestern
blot analysis of conditioned media (Figure S8C). Microglia were
then isolated from the mixed glial culture, and phagocytosis of
preformed fluorescent fAb was examined by immunofluores-
cence and flow cytometry. Microglial cells isolated from the
ApoE-treated culture and maintained in ApoE-conditioned me-
dia showed a striking attenuation in internalization of fAb
compared to control microglia grown in GFP-conditioned media
(p = 0.0027) (Figures 8E and S8D). Given the evidence for high-
affinity binding of ApoE to Ab, we exploredwhether a direct inter-
action between Ab aggregates and ApoE in the glial-conditioned
media might account for the dramatic effect on phagocytosis
(Figure 8F). A pull-down assay using control aggregated amy-
loids (Iconomidou et al., 2001; Wilkins et al., 2000), aggregated
Ab42, and aggregated reverse Ab42 showed that ApoE binds
selectively to aggregated Ab42 but not to the other amyloids
(Figure 8F).
DISCUSSION
In this study, we have directly tested the hypothesis that ex-
pression of the anti-inflammatory cytokine IL-10 would have
beneficial effects in two APPmouse models. Rather than finding
beneficial effects, we found that IL-10 worsens multiple AD-rele-
vant phenotypes in APP mice, including amyloid plaque pathol-
ogy and memory and learning. There was no evidence that the(E) Microglia grown in ApoE-conditioned media internalize less fAb40 compared t
Hilyte555 was conducted following exposure to Ab for 30 min. Representative da
Data represent mean ± SEM.
(F) Amyloid pull-down assay shows that aggregated Ab42 specifically binds ApoE
silkmoth chorion polypeptides 1–51; CS 35, bacterial cold shock polypeptides 1
(G) Mechanistic insights into the proamyloidogenic effects of IL-10. IL-10 can d
astroglial phagocytosis and removal of Ab by binding to Ab in plaques.
See also Figure S8.pro-amyloidogenic effect was due to altered APP expression
or processing, nor were levels of key Ab-degrading enzymes
altered. IL-10 had a complex effect on innate immune activation
status in the brain. IL-10 altered the innate immune gene expres-
sion toward a M2-like activation state. Simultaneously, a net-
work-based approach identified several inflammatory pathways
consisting of chemokines and acute phase reactants to be upre-
gulated in IL-10-expressing Tg and nTg mice.
Mechanistically, we can attribute the negative effects of IL-10
on Ab proteostasis to synergistic effects of decreased Ab phago-
cytosis by microglia, increased endogenous ApoE expression,
and enhanced accumulation of ApoE in insoluble amyloid pla-
ques (summarized in Figure 8G). Our Ab phagocytosis data, in
combination with previous data with inflammatory cytokines
(Chakrabarty et al., 2010a), indicate that IL-10-mediated alter-
ations of innate immunity dampen microglial phagocytosis of
Ab in vitro. Additionally, ApoE by binding with Ab aggregates,
may negatively regulate Ab aggregate clearance, thereby pro-
moting further plaque deposition. Human APOE has been shown
to have complex effects on Ab. It promotes deposition of fibrillar
Ab and, in humans, can regulate clearance of soluble Ab in an
isoform-dependent manner (reviewed in Liu et al., 2013). Not
only are human APOE4 carriers at risk for developing AD, but
APOE4 may also have negative impact on cognition in normal
aging and AD (Corder et al., 1993; Deary et al., 2002; Honea
et al., 2009; Liu et al., 2014). Mouse ApoE is comparable to hu-
man APOE4 at residues 112 and 158, and numerous studies
suggest that the mouse protein may have enhanced amyloido-
genic properties (Bales et al., 1997; DeMattos et al., 2004; Fagan
et al., 2002; Holtzman et al., 2000a). Knocking out both endoge-
nous mouse ApoE alleles reduces Ab plaque deposition in APP
mice (Holtzman et al., 2000a), and even haploinsufficiency re-
duces amyloid loads (Kim et al., 2011). Similarly, overexpression
of APOE4 in predepositing APPmice exacerbates Ab pathology,
whereas overexpression of APOE2 can enhance clearance of
preexisting deposits (Dodart et al., 2005; Hudry et al., 2013). In
our study, the increased level of insoluble ApoE is plaque asso-
ciated, which is consistent with mouse ApoE functioning as a
pathological chaperone promoting Ab fibrillogenesis (Bales
et al., 1999; Holtzman et al., 1999, 2000b; Wisniewski et al.,
1994). This is consistent with our immunofluorescence and am-
yloid pull-down data that mouse ApoE preferentially associates
with fibrillar Ab, suggesting that the behavioral and amyloido-
genic phenotype induced by IL-10 can result from the accumu-
lation of Ab bound to ApoE and, possibly, neurotoxic cleavage
fragments (Cho et al., 2001; Jones et al., 2011; reviewed in Mah-
ley and Huang, 2012). However, it remains to be seen whether
increasing the ‘‘protective’’ forms of ApoE (ApoE2) can result in
an opposite phenotype in the presence of IL-10, i.e., bindingo GFP-conditioned media. Flow cytometric analysis for the presence of Ab40-
ta from two experiments are presented. **p < 0.01, unpaired two-tailed t test.
in media. Representative assay from two independent experiments. ChA silk,
–35.
irectly dampen microglial phagocytosis; ApoE, induced by IL-10, may inhibit
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and clearing Ab. Thus, the present study demonstrates that a key
anti-inflammatory cytokine exacerbated Ab proteostasis and
brain function by altering Ab clearance and/or deposition. These
observations are highly consistent with unpublished data
showing that IL-10 deficiency in APP mice dramatically reduces
Ab load and other AD-related phenotypes, including lowered
ApoE levels by RNA-seq analysis (log2 fold change = 0.6,
FDR = 4 3 105) (Guillot-Sestier et al., 2015).
These data are also highly consistent with our previous but
relatively limited study, showing that direct intracranial expres-
sion of IL-4, another key anti-inflammatory cytokine, results in
Ab plaque accumulation in TgCRND8 mice (Chakrabarty
et al., 2012). Furthermore, the data also agree with our previ-
ously published findings that proinflammatory cytokines (IL-6,
TNF-a, and IFN-g) attenuated Ab plaque deposition and
increased microglial Ab phagocytosis (Chakrabarty et al.,
2010a, 2010b, 2011). Thus, in contrast to the long-standing hy-
pothesis that proinflammatory stimuli promote Ab deposition,
we find the opposite: anti-inflammatory stimuli promote amy-
loid deposition.
In two recent studies, AAV-mediated hippocampal targeted
expression of IL-10 and IL-4 were reported to decrease gliosis
and improve spatial memory in APP/PS1 mice (Kiyota et al.,
2010, 2012). Moreover, IL-4, but not IL-10, was reported to
attenuate plaque deposition in these mice. Given that our IL-10
data were reproduced in two independent CRND8 cohorts and
in a hippocampal paradigm in the Tg2576 mouse model, and
given that a robust proamyloidogenic effect of IL-4 was
observed both histochemically and confirmed biochemically in
TgCRND8mice (Chakrabarty et al., 2012), it is not easy to recon-
cile our observations with these previous reports. We note that
the group sizes in the Kiyota study are low, especially for behav-
ioral analyses. Moreover, they do not specify gender of the mice,
which can influence both behavioral effects and plaque loads in
the bigenic APP/PS1mice (Wang et al., 2003). It is also possible
that the source of the discrepant observations could be attrib-
uted to the use of familial AD-linked mutant PSEN1 transgenic
mice, as PSEN1 has been reported to have immunomodulatory
actions in the brain (Choi et al., 2008).
Although our own studies in this area have been internally
consistent, a broader survey of published studies regarding
alterations of Ab and other phenotypes in APPmice via manipu-
lation of chemokines, cytokines, and other innate immune mod-
ulators suggests that a unified view of immunoproteostasis
mechanisms in AD is not feasible at this time (Czirr and Wyss-
Coray, 2012). Manipulations such as LPS, TLR agonists, or as-
trocytic overexpression of inflammatory cytokine IL-1b, which
induce inflammatory glial activation, reduce plaque load (Herber
et al., 2007; Scholtzova et al., 2009; Shaftel et al., 2007). Thus,
coupled with our previous observations in IL-6, IFN-g, and
TNF-a overexpression paradigms in CRND8 mice (Chakrabarty
et al., 2010a, 2010b, 2011), these studies suggest that, at least
with respect to Ab-related phenotypes, a proinflammatory envi-
ronment may have beneficial outcomes. However, other manip-
ulations that can have an anti-inflammatory effect have also been
shown to reduce plaques and improve cognition. Notable recent
examples include genetic deficiency of inflammasome (Nlrp3 or
Casp1 knockouts), deficiency of Mrp14, and loss of IL-12/IL-23530 Neuron 85, 519–533, February 4, 2015 ª2015 Elsevier Inc.signaling (Heneka et al., 2013; Vom Berg et al., 2012). Further
additional manipulations (for example, loss of CD14, CD40L,
Myd88, fractalkine signaling, TGF-b signaling, or overexpression
of TGFb1) can have complex, and sometimes unexpected, ef-
fects on AD-relevant phenotypes in mouse models that can be
challenging to reconcile with data from similar paradigms (Lee
et al., 2010; Lim et al., 2011; Reed-Geaghan et al., 2010; Tan
et al., 1999; Town et al., 2008; Wyss-Coray et al., 2000).
Though genetic association studies have not reproducibly es-
tablished the association of SNPs within the IL-10 gene with AD
risk, the recent and unequivocal associations of SNPs within
other genetic loci that encode innate immunity genes bolster
the preclinical data that innate immunity has a significant role
in AD (Depboylu et al., 2003; Griciuc et al., 2013; Guerreiro
et al., 2013; Kamboh et al., 2012; Lambert et al., 2013). In spite
of a clear contribution of immunoproteostasis in AD, epidemio-
logic and clinical data largely focused on NSAID use and AD
risk reveal a fairly conflicted literature related to anti-inflamma-
tory strategies. Long-term NSAID use has been repeatedly
shown to confer protection in epidemiologic studies (Szekely
et al., 2004), but subsequent clinical trials with celecoxib and
naproxen have not shown any benefits in patients (Martin
et al., 2008). Given that select NSAIDs can modulate Ab produc-
tion, inhibit Ab aggregation, and affect other cell signaling path-
ways, it is possible that any potential protective effect of these
NSAIDs could be due to target engagement other than cycloox-
ygenase (Lim et al., 2000; Weggen et al., 2001). A final intriguing
observation relating to human NSAID use and AD is a report
showing that naproxen use was associated with increased post-
mortem brain Ab pathology (Sonnen et al., 2010). Though other
pharmacologic approaches that might have anti-inflammatory
effects (e.g., statins and PPARg/a agonists) have been reported
to have potential therapeutic benefit in AD preclinical models, to
date, none have shown efficacy in clinical trials, nor has the effect
in preclinical studies been unequivocally linked to effects on im-
munoproteostasis (Gold et al., 2010; Sano et al., 2011).
A striking feature of our study is the synergistic effect of IL-10
induced Ab accumulation on fear-conditioned memory and syn-
aptic protein levels. As noted, IL-10 had minimal effect on
learning and memory in the nTg littermates, but in the TgCRND8
transgenic mice, it significantly exacerbated context and tone
fear memory, concurrent with marked loss of synaptic proteins.
Although many studies suggest that soluble oligomeric species
of Ab are most often associated with various memory impair-
ments in APP mice and humans (Zahs and Ashe, 2013), in
TgCRND8mice, we have seen a strong correlation between total
Ab loads and impairments in fear-conditioned memory (Hanna
et al., 2012). Notably, multiple studies also show that increased
insoluble APOE, both in humans and mice, is associated with
worse cognitive function, which is consistent with our observa-
tions (Bennett et al., 2005; Nilsson et al., 2004; Raber et al.,
2000).
The observation that IL-10 can increase ApoE expression and
promote its codeposition with Ab has implications for AD ther-
apy. There is ample evidence that promoting expression of
the protective APOE2 isoform would have beneficial effects
and APOE4 harmful effects; thus, we might expect that
increased IL-10 or any factor that promotes APOE expression
in humans may have genotype-dependent effects. Indeed, in
the context of APOE2, one would propose that IL-10 could be
beneficial if its effect on APOE is dominant. In contrast, given
the intermediate amyloid-promoting effects of APOE3, empirical
studies would be needed to determine effects of IL-10 in the
context of APOE3.
In conclusion,wehavedemonstrated that IL-10expression has
a proamyloidogenic effect in APP mice leading to dysfunctional
immunoproteostasis, impaired memory, and reduction of synap-
ticmarkers. Thesedata further highlight thecomplex role of innate
immune activation in AD and other neurodegenerative diseases
where specific innate manipulations can have unexpected posi-
tive or negative effects on proteostasis and neurodegeneration.
EXPERIMENTAL PROCEDURES
Animal Models and AAV2/1 Injection
All animal procedures were approved by the Institutional Animal Care and Use
Committee and conducted as described elsewhere (Chakrabarty et al.,
2010a). See Supplemental Experimental Procedures for details.
Western Blot, Immunohistochemistry, ELISA, and RNA Analysis
See Supplemental Experimental Procedures for details.
Contextual Fear Conditioning
See Supplemental Experimental Procedures and Figure 3A for details.
Ab Phagocytosis
Wild-type murine microglia or astrocyte cultures were evaluated for uptake of
fluorescently labeled fAb42 or fAb40 in the presence of cytokines. See Supple-
mental Experimental Procedures for details.
RNA Analysis
Transcriptome data obtained from the NanoString array were analyzed using
NanoStringNorm R, IPA, and DIRAC as described in Supplemental Experi-
mental Procedures. The q values were obtained as described elsewhere (Sto-
rey and Tibshirani, 2003). The raw data have been deposited at https://www.
synapse.org/#!Synapse:syn2866151.
Statistical Analysis
A one-way or two-way ANOVA with Tukey’s multiple comparison test was
used for statistical comparison unless otherwise stated (SigmaStat 3.0
version). For t tests, multiple comparison test parameters were applied, con-
trolling for a false discovery rate of 5%. Graphical analyses were conducted
using Prism 5 (GraphPad Software), and final images were created using Pho-
toshop CS2 (Adobe).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight figures, and five tables and can be found with this article online at
http://dx.doi.org/10.1016/j.neuron.2014.11.020.
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